ClinicalTrials.gg
Not yet recruitingNCT07712588Updated Aug 5, 2026

Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

A Phase 2/3 interventional study of Birelentinib and Rituximab in Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Dizal Pharmaceuticals. Not yet recruiting at 5 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Dizal Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China — 143 open to participants now, 165 under way, 31 of them phase 3. Lymphoma, Large B-Cell, Diffuse · China.

Planned enrollment
6th of 277
880 · median 59
Started
2026
with 29 others
Phase 2/3
6 of 306
3 open now
Primary completion
2031-01
later than 163 of 164 live
Registered
296th of 306
by date

Among the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, this one is the 6th largest by planned enrollment of the 277 interventional ones that give a count, is one of 30 that started in 2026, is one of 6 in phase 2/3, reaches primary completion later than 163 of the 164 other live ones, and was the 296th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

143 of the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, or all of them as a file.
02

Study summary

This study will treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of birelentinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma (DLBCL)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-70 years
  • score 0-2
  • confirmed DLBCL unspecified (DLBCL, NOS)
  • No prior anti-lymphoma therapy
  • Ann Arbor Stages II - IV
  • IPI score ≥ 3, or IPI score 1 - 2 and LDH > 1.3 × and/or lesion diameter ≥ 7 cm
  • Adequate bone marrow and organ function
  • Willing to comply with restrictions

Exclusion criteria

Exclusion Criteria:

  • Indolent lymphoma or Richter transformation, primary mediastinal lymphoma, lymphoma invading the central nervous system or high-grade lymphoma with MYC and BCL2 rearrangements.
  • Vaccination with or viral vector vaccines within 4 weeks prior to treatment.
  • Taking vitamin K antagonists, taking 2 or more antiplatelet/anticoagulant drugs at the same time, drugs/herbs or supplements known to potently induce or inhibit enzyme activity, anti-tumor traditional Chinese medicine.
  • Major surgery within 4 weeks or anticipated surgery after the start of this study.
  • cardiac disorders. History of thrombotic diseases, stroke or intracranial hemorrhage within 6 months.
  • Active infectious diseases.
  • Peripheral neuropathy ≥ Grade 2 (as defined by version 6.0)
  • Intractable nausea and vomiting that cannot be well controlled by supportive treatment, chronic gastrointestinal diseases, dysphagia, or previous surgical resection of the intestinal segment may affect the adequate absorption of the drug.
  • Diagnosed with other malignant diseases other than B-cell lymphoma within the past 2 years.
  • Patients with severe or uncontrolled systemic diseases, including poorly controlled hypertension and active bleeding constitution.
  • Patients with a history of to any component of the R-CHOP regimen, DZD8586 drug , or other chemical analogues.
  • Serious medical or psychiatric illness that could affect participation in the study or could compromise the ability to consent.
  • Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
880 participants (estimated)

Study arms

  • Experimental
    Birelentinib + R-CHOP (Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone)

    Drug: Birelentinib · Drug: Rituximab · Drug: Cyclophosphamid · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone

  • Placebo comparator
    Placebo + R-CHOP

    Drug: Rituximab · Drug: Cyclophosphamid · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Placebo

Interventions

  • Specified dose on specified days

    Also known as: DZD8586

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Part A: Incidence and severity of adverse events

    Time frame: Up to 2 years

  2. Part B: Progression-free survival (PFS)

    Time frame: Up to 5 years

Secondary outcomes

  1. Part A: Objective response rate (ORR)

    Time frame: Up to 5 years

  2. Part A: Complete response rate (CRR)

    Time frame: Up to 5 years

  3. Part B: Event-free survival (EFS)

    Time frame: Up to 5 years

  4. Part B: Overall Survival (OS)

    Time frame: Approximately 5 years

  5. Part B: Objective response rate (ORR)

    Time frame: Up to 5 years

  6. Part B: Complete response rate (CRR)

    Time frame: Up to 5 years

  7. Part B: Incidence and severity of adverse events

    Time frame: Up to 2 years

07

Study locations

5 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Jan 2031, 52 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartEst.
Sep 2026
Primary completionEst.
Jan 2031
CompletionEst.
Feb 2032
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07712588
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jan 2031 (estimated)
Completion
Feb 2032 (estimated)
Last update
Aug 5, 2026

Study contacts

Liu
Contact
ziyi.liu@dizalpharma.com
+86-21-61095852
Zhao
principal investigator · Ruijin Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Birelentinib

Start the discussion